Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Conditions
Interventions
SPH4336 Tablets 400mg
SPH4336 Tablets Placebo
Locations
9
China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
AnYang Tumor Hospital
Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Start Date
April 24, 2023
Primary Completion Date
May 31, 2026
Completion Date
May 31, 2026
Last Updated
August 17, 2025
NCT07354022
NCT02926690
NCT06680921
NCT07461454
NCT02514681
NCT03027245
Lead Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions